目的 探讨盐酸安罗替尼维持治疗一线化疗后晚期肺鳞癌的疗效及安全性.方法 收集40例晚期肺鳞癌患者,已完成4～6个疗程标准化疗,应用随机抽签的方式将患者分为试验组及对照组,每一组20例患者,对照组给予最佳支持治疗,实验组给予安罗替尼维持治疗,比较两组PFS、血清VEGFR水平、KPS评分及安全性.结果 试验组和对照组的中位PFS分别为8.7个月和4.5个月(P＜0.05).维持治疗开始前试验组与对照组患者血清中血管内皮生长因子(VEGF)水平比较差异无统计学意义(P＞0.05),治疗后试验组患者血清中VEGF-2水平明显低于对照组(260.44±17.32 vs 320.15±19.04)pg/ml,P＜0.05).盐酸安罗替尼治疗后患者KPS评分基本维持在1分.患者不良反应轻,主要为高血压、手足综合征及黏膜溃疡,经治疗后均能缓解.结论 盐酸安罗替尼维持治疗一线化疗后病情稳定的晚期肺鳞癌患者,可提高PFS,维持较好的KPS评分,安全性好.
Clinical Efficacy of Arotinib Hydrochloride for Advanced Lung Squamous Cell Carcinoma
Objective To explore the efficacy and safety of maintenance therapy with arotinib hydrochloride for ad-vanced lung squamous cell carcinoma after first-line chemotherapy.Methods 40 patients with advanced lung squamous cell car-cinoma who had completed 4～6 courses of standard chemotherapy were collected and randomly divided into the experimental group and the control group.Each group had 20 patients,and the control group received the best supportive treatment.The experi-mental group received maintenance treatment with arotinib.PFS,serum VEGFR levels,KPS scores,and safety were compared be-tween the 2 groups.Results The median PFS of the experimental group and the control group were 8.7 months(95％CI:6.7～11.0)and 4.5 months(95％CI:3.7～6.0),respectively(P＜0.05).Before the start of maintenance treatment,there was no statistically significant difference in the serum levels of vascular endothelial growth factor(VEGF)between the experimental group and the control group(P＞0.05).After treatment,the serum VEGF-2 levels in the experimental group were significantly lower than those in the control group(260.44±17.32 vs 320.15±19.04)pg/ml,P＜0.05).After treatment with arotinib hydrochlo-ride,the patient's KPS score remained basically at 1 point.The patient has mild adverse reactions,mainly hypertension,hand foot syndrome,and mucosal ulcers,which can be alleviated after treatment.Conclusion Anlotinib hydrochloride maintenance therapy can improve PFS,maintain a good KPS score,and have good safety in patients with advanced lung squamous cell carcinoma who have stable conditions after first-line chemotherapy.
万方数据
维普
